Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

The purpose of this study is to evaluate the safety of TAK-438, once daily (QD), during long-term concomitant low-dose aspirin therapy in patients with a history of gastric or duodenal ulcer who require long-term therapy of low-dose aspirin.

Condition or disease	Intervention/treatment	Phase
Gastric Ulcers; Duodenal Ulcers	Drug: TAK-438; Drug: Placebo; Drug: Lansoprazole	Phase 3

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	439 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Single (Participant)
Primary Purpose:	Prevention
Official Title:	A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Low-dose Aspirin
Study Start Date :	March 2012
Actual Primary Completion Date :	October 2013
Actual Study Completion Date :	October 2013

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: TAK-438 10 mg QD	Drug: TAK-438; TAK-438 10 mg tablets, orally, once daily for 28-80 weeks. Drug: Placebo; Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
Experimental: TAK-438 20 mg QD	Drug: TAK-438; TAK-438 20 mg tablets, orally, once daily for 28-80 weeks. Drug: Placebo; Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
Active Comparator: AG-1749 15 mg QD	Drug: Lansoprazole; Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.; Other Name: AG-1749 Drug: Placebo; TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Incidence of treatment-emergent adverse events [ Time Frame: Up to 80 weeks. ]
   Treatment-emergent adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through the last visit of study.

Secondary Outcome Measures :

1. Change from baseline in Laboratory values [ Time Frame: Up to 80 weeks. ]
2. Change from baseline in Electrocardiograms [ Time Frame: Up to 80 weeks. ]
3. Change from baseline in Vital signs [ Time Frame: Up to 80 weeks. ]
4. Change from baseline in Serum gastrin [ Time Frame: Up to 80 weeks. ]
5. Change from baseline in Pepsinogen I and II [ Time Frame: Up to 80 weeks. ]
6. Recurrence rate of gastric or duodenal ulcer [ Time Frame: Up to 80 weeks. ]

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	20 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

1. Participants who require continuous low-dose aspirin therapy during the treatment period with the study drug
2. Participants who have completed the preceding study
3. Outpatient (including inpatient for examinations)

Exclusion Criteria:

1. Participants deemed to be ineligible to participate in the study by the principal investigator or investigator due to the occurrence of adverse events in the preceding study
2. Participants who are scheduled to change the type and dosage regimen of low-dose aspirin
3. Participants with ulcers or bleeding in stomach or duodenum, endoscopically confirmed during the preceding study
4. Participants with small intestine bleeding, large intestine bleeding, or gastrointestinal bleeding of unknown etiology
5. Participants who have a history of surgery which affects gastric acid secretion (e.g., resection of upper gastrointestinal tract, vagotomy) or who are scheduled to undergo such surgery
6. Participants with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders
7. Participants with a previous or current history of aspirin-induced asthma

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

  Show 76 Study Locations

Sponsors and Collaborators

Takeda

Investigators

Study Director:	Senior Manager	Takeda

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Kawai T, Oda K, Funao N, Nishimura A, Matsumoto Y, Mizokami Y, Ashida K, Sugano K. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut. 2017 Dec 1. pii: gutjnl-2017-314852. doi: 10.1136/gutjnl-2017-314852. [Epub ahead of print]

Responsible Party:	Takeda
ClinicalTrials.gov Identifier:	NCT01456247 History of Changes
Other Study ID Numbers:	TAK-438/OCT-302; U1111-1123-9658 ( Registry Identifier: WHO ); JapicCTI-111616 ( Registry Identifier: JapicCTI )
First Posted:	October 20, 2011
Last Update Posted:	May 8, 2014
Last Verified:	May 2014

Keywords provided by Takeda:

Drug Therapy

Additional relevant MeSH terms:

Ulcer; Stomach Ulcer; Duodenal Ulcer; Pathologic Processes; Peptic Ulcer; Duodenal Diseases; Intestinal Diseases; Gastrointestinal Diseases; Digestive System Diseases; Stomach Diseases; Aspirin; Lansoprazole; Dexlansoprazole; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic	Analgesics; Sensory System Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Anti-Inflammatory Agents; Antirheumatic Agents; Fibrinolytic Agents; Fibrin Modulating Agents; Molecular Mechanisms of Pharmacological Action; Platelet Aggregation Inhibitors; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Antipyretics; Anti-Ulcer Agents; Gastrointestinal Agents